Roche Diagnostics Scandinavia AB and NorDiag ASA have signed a new collaboration agreement. The agreement grants Roche Diagnostics Scandinavia AB non-exclusive rights to market and sell NorDiag`s new automated sample preparation for sexually transmitted infections to existing and new users of the Roche COBAS® TaqMan® 48 Analyzer in Sweden.

The agreement follows a successful clinical trial combining NorDiag`s sample preparation instrument and kits with the Roche COBAS® TaqMan® 48 Analyzer. The clinical trial was executed at Borås Hospital in Sweden.

NorDiag`s method creates a fully automated process for the whole sexually transmitted infections value chain, helping to increase speed and reduce costs in the laboratory.

Contact:
CEO Mårten Wigstøl, Phone: +47 91165775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the Notice in Norwegian here